Pulmonology

Expert pulmonologists comment on emerging therapies in the pipeline for the treatment of IPF.

Fernando J. Martinez, MD, MS, and Steven D. Nathan, MD, FCCP, share their personal experiences using pirfenidone and nintedanib in clinical practice and discuss the role of managing comorbidities for the treatment of IPF.

Experts in pulmonology discuss the safety and efficacy of pirfenidone and nintedanib for the management of IPF.

Drs Fernando J. Martinez and Steven D. Nathan review the goals of therapy and the importance of non-pharmacological therapies for the management of IPF.

Steven D. Nathan, MD, FCCP, leads the discussion on the differential diagnosis of idiopathic pulmonary fibrosis (IPF).

Expert pulmonologists discuss the effect of early and late diagnosis on IPF disease management, as well as the importance of a multidisciplinary team approach to treatment.

With the concept of a “twindemic” becoming more realistic than ever, experts are stressing that preventive practices, and vaccination, address both flu and COVID-19.

Investigators suggested that peer-led asthma program implemented in venues such as schools, houses of worship, or clinics can improve access to asthma education.

Authors suggest children with uncontrolled asthma should be considered for priority for COVID-19 vaccination.

Investigators recorded “remarkable variation” in CLRD hospitalization and mortality rates in 62 counties in New York state.

Dr. Mulshine and Dr. Rizzo discuss the diagnostic evolution detailed in several studies in the previous decades, and how CT screening can be used to detect lung cancer early in patients.

In recognition of Lung Cancer Awareness Month, this episode featuring Dr. James Mulshine at Rush University explains the ins and outs of the improved 2021 lung cancer screening guidelines.

Investigators also found a high prevalence between OSAS, nasal polyps, nutritional status, and other clinical variables.

Steven D. Nathan, MD, FCCP, provides an overview of idiopathic pulmonary fibrosis, including long-term disease complications and the effect on a patient’s quality of life.

The treatment cannot be granted full approval due to ongoing litigation.

To date, dupilumab is the only medicine to show clinically meaningful phase 3 results in this patient population, with regulatory fillings planned for 2022.

The REVEAL Lite 2 risk assessment tool confirmed that treatment with the agonist improved risk profile and long-term outcomes of patients with pulmonary arterial hypertension.

The indication makes 6 to 11-year-old children with eosinophilic biomarkers or corticosteroid dependency eligible for the biologic add-on therapy.

Investigators propose oral treprostinil be considered when treating patients with pulmonary arterial hypertension.

ILD is a very broad category of chronic lung conditions with considerable nuance. Glassberg joins to discuss the roles of biomarkers, biopsies and drugs, as well as multidisciplinary clinics and stem cell therapy.

A higher proportion of newly diagnosed patients with PAH showed improved risk status after the initiation of the oral prostacyclin receptor agonist.

Investigators noted that the agonist was particularly effective in patients with severe PAH who were receiving spironolactone.

The letter pointed to a single deficiency related to an open inspection issue at a third-party facility.

The indication came via the Premarket Tobacco Product Application, which requires evidence of public health benefit and company agreement to post-marketing strategies that avoid young users.

There were no episode of gastrointestinal bleeding, transfusion of packed red blood cells, or octreotide infusions observed.